FDA Panel Favors Approval of Alirocumab and Evolocumab for Hypercholesterolemia

FDA Panel Favors Approval of Alirocumab and Evolocumab for Hypercholesterolemia.  Two PCSK9 inhibitors have been recommended for approval. The agency will likely follow the advisory committee’s advice when it decides whether to approve the drugs, alirocumab (Praluent) from Sanofi SA and Regeneron Pharmaceuticals Inc., and evolocumab (Repatha) from Amgen Inc., for patients later this summer.They are especially good for people who cannot take statins due to their side effects.

Panasonic Healthcare to Buy Bayer’s Diabetes Business for $1.15 Billion.